-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The industry has long been rumoured that BMY, the pharmaceutical giant, is going to be acquired, and if that's true, there's one company that has the power but won't make a bid, and that's Pfizer (PFE).
blog on Barron' investment website explains why Pfizer is unlikely to bid. The blog quoted Deutsche Bank's Greg Gilbert and Esther Rajavel as commenting on StreetInsider, noting that Pfizer would not bid because such a deal "would be a huge opportunity/risk for the immune oncology sector (market value $90 billion plus premium), which is fraught with short-term uncertainty and which Pfizer has deployed at least in part." Two analysts said Pfizer would prefer to look for "more diversified value dynamics" and "cost-effective projects" if it were to invest heavily in such a large company
BioSpace reported earlier this week that at least four large-cap companies were said to be interested in buying PepsiCo, including Pfizer. But if Pfizer is ruled out, three companies, GILD, Novart (NVS) and Switzerland's RHHBY, could bid.
has lost more than 15 per cent of its shares since January 10 and is now valued at about $50bn. Earlier this month, the company lowered its profit forecast for 2017. Although the loss of market share is not small, hundred-time Meishi Guibao asking price will be relatively high. Analysts at Deutsche Bank suggested $90m, but some forecast the company could sell for as much as $120m.
the rumors have been hot, but the board of directors of Shishi Shiguibao has not expressed its willingness to accept any offer.
, according to a recent Bloomberg report, The Times has dropped from fourth to ninth place on america's most valuable list. That's largely because last year's failure of its main PD-1 inhibitor, Opdivo, hit the company hard. In August 2016, the Phase III clinical data released by Shishi Shiguibao showed that Opdivo failed to reach the trial point of PD-L1 expression of no progress in lung cancer patients. The defeat created a good opportunity for rival MERCK's PD-1 inhibitor Keytruda to grab market share. The company is concerned that Keytruda will be approved as a first-line treatment for lung cancer. As a result of Merck's success, the company is not counting on the Food and Drug Administration's rapid approval of the Optivo portfolio, but some analysts say it suggests the data is questionable.
Opdivo not only faces the threat of Keytruda competing for market share, but Roche's Tecentriq took 10 percent of the market from Opdivo in the fourth quarter of 2016. (Health)